N-[2-(Piperidin-1-YL)ethyl]pyridine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-[2-(Piperidin-1-YL)ethyl]pyridine-2-carboxamide
• 英文别名: N-(2-piperidin-1-ylethyl)pyridine-2-carboxamide
• 化学式: C₁₃H₁₉N₃O
• mdl: MFCD01101295
• 分子量: 233.31
• InChiKey: YDSZTZIVJFBEMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  45.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR THE TREATMENT OF CANCER
  申请人：CHIRON CORPORATION

  公开号：EP1680122A1

  公开（公告）日：2006-07-19
• [EN] 2,6-DISUBSTITUTED QUINAZOLINES, QUINOXALINES, QUINOLINES AND ISOQUINOLINES AS INHIBITORS OF RAF KINASE FOR TREATMENT OF CANCER<br/>[FR] QUINOXALINES, QUINOLINES, ISOQUINOLINES ET QUINAZOLINES 2,6-BISUBSTITUEES SERVANT D'INHIBITEURS A LA KINASE RAF POUR LE TRAITEMENT DU CANCER
  申请人：CHIRON CORP

  公开号：WO2005037285A1

  公开（公告）日：2005-04-28

  New substituted quinazoline, quinoxaline, quinoline and isoquinoline compounds of formulae (I)-(IV), compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer. The substituents are defined in the claims.